Antiangiogene Therapie am Auge - bewährte und neue Therapieansätze

Zusammenfassung

Aus der Onkologie kommend hat die antiangiogene Therapie die Augenheilkunde in den letzten Jahren verändert. Sie eröffnet neue Optionen für die Behandlung der altersabhängigen Makuladegeneration, des diabetischen Makulaödems, nach Venenverschlüssen und möglicherweise auch von Erkrankungen der Hornhaut mit starker Blut- und Gefäßneubildung. In dieser Arbeit soll ein Überblick über neue medikamentöse therapeutische Strategien gegeben werden, die sich derzeit in der klinischen Erprobung oder Anwendung befinden.

Abstract

Originating from therapeutic concepts in oncology, angioinhibitory strategies have changed the way ophthalmological patients are treated for a variety of diseases like age-related macular degeneration, diabetic retinopathy or retinal vein occlusion. It is likely that these therapeutic options will not be limited to retinal disease, but will also prove useful for corneal disorders associated with lymph- or angiogenesis. This review is intended to provide a concise overview of the current options investigated in clinical trials.

Schlüsselwörter

Pharmakologie - Retina - Kornea

Key words

retina - pharmacology - cornea

Literatur

• 1 Campochiaro P A. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412.  Invest Ophthalmol Vis Sci. 2004;  45 922-931
• 2 Campochiaro P A, Nguyen Q D, Shah S M. et al . Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial.  Hum Gene Ther. 2006;  17 167-176
• 3 Connolly B, Desai A, Garcia C A. et al . Squalamine lactate for exudative age-related macular degeneration.  Ophthalmol Clin North Am. 2006;  19 381-91
• 4 Cursiefen C, Cao J, Chen L. et al . Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival.  Invest Ophthalmol Vis Sci. 2004;  45 2666-2673
• 5 Cursiefen C, Chen L, Saint-Geniez M. et al . Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision.  Proc Natl Acad Sci USA. 2006;  103 11 405-11 410
• 6 Cursiefen C, Rummelt C, Junemann A. et al . Absence of blood and lymphatic vessels in the developing human cornea.  Cornea. 2006;  25 722-726
• 7 D’Amico D J, Goldberg M F, Hudson H. et al . Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes.  Ophthalmology. 2003;  110 2372-2383
• 8 Fiedler U, Reiss Y, Scharpfenecker M. et al . Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation.  Nat Med. 2006;  12 235-239
• 9 Folkman J. Tumor angiogenesis: therapeutic implications.  N Engl J Med. 1971;  285 1182-1186
• 10 Gragoudas E S, Adamis A P, Cunningham E T. et al . Pegaptanib for neovascular age-related macular degeneration.  N Engl J Med. 2004;  351 2805-2816
• 11 Jonas J B, Schlichtenbrede Jr F. Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases.  Eye. 2007;  E-pub.
• 12 Junker B, Schmidt D, Agostini H T. Angiomatosis retinae.  Ophthalmologe. 2007;  104 107-113
• 13 Kaushik S, Gupta V, Gupta A. et al . Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion.  Am J Ophthalmol. 2004;  137 758-760
• 14 Kube T, Sutter M, Trittler R. et al . Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone.  Graefes Arch Clin Exp Ophthalmol. 2006;  244 1385-1390
• 15 Ladomery M R, Harper S J, Bates D O. Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm.  Cancer Lett. 2007;  249 133-142
• 16 Lynch S S, Cheng C M. Bevacizumab for neovascular ocular diseases.  Ann Pharmacother. 2007;  41 614-625
• 17 Maier P, Unsoeld A S, Junker B. et al . Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787 /ZK222 584 improves ischemia-induced retinopathy in mice.  Graefes Arch Clin Exp Ophthalmol. 2005;  243 593-600
• 18 Martin G, Schlunck G, Hansen L L. et al . Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium.  Graefes Arch Clin Exp Ophthalmol. 2004;  242 321-326
• 19 Michaelson I C. .  Trans Ophthalmol Soc UK. 1948;  68 137-180
• 20 Michels S, Agostini H AT. Inhibition der Angiogenese in der Augenheilkunde. Bremen; Uni-Med Verlag 2007
• 21 Mross K. Angiogeneseinhibitoren in der Onkologie. Bremen; Uni-Med Verlag 2007
• 22 Ng Y S, Krilleke D, Shima D T. VEGF function in vascular pathogenesis.  Exp Cell Res. 2006;  312 527-537
• 23 Nguyen Q D, Shah S M, Hafiz G. et al . A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.  Ophthalmology. 2006;  113 1522
• 24 Perrin R M, Konopatskaya O, Qiu Y. et al . Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor.  Diabetologia. 2005;  48 2422-2427
• 25 Rosenfeld P J, Brown D M, Heier J S. et al . Ranibizumab for neovascular age-related macular degeneration.  N Engl J Med. 2006;  355 1419-1431
• 26 Stahl A, Agostini H, Hansen L L. et al . Bevacizumab in retinal vein occlusion-results of a prospective case series.  Graefes Arch Clin Exp Ophthalmol. 2007;  245 1429-1436
• 27 Umeda N, Kachi S, Akiyama H. et al . Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist.  Mol Pharmacol. 2006;  69 1820-1828
• 28 Wood J M, Bold G, Buchdunger E. et al . PTK787 /ZK 222 584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.  Cancer Research. 2000;  60 2178-2189